-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190

Benzinga·07/16/2026 12:00:31
Listen to the news
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $160 to $190.